Megyeri, AttilaTsai, Ping Lien2025-04-232025-04-232025https://hdl.handle.net/2437/389317Around 85% of lung cancer cases are non-small cell lung cancer (NSCLC). Recent treatment used for NSCLC has been changed to immunotherapy, especially immune checkpoint inhibitors (ICIs), such as PD-1/PD-L1 and CTLA-4 inhibitors. These treatments increase the overall survival (OS) and progression-free survival (PFS) of patients.36enNon-small cell lung cancerMedicine::PharmacologyHozzáférhető a 2022 decemberi felsőoktatási törvénymódosítás értelmében.